Alpine Immune Sciences (STU:34LA) Cash-to-Debt : 33.03 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Alpine Immune Sciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Alpine Immune Sciences's cash to debt ratio for the quarter that ended in Dec. 2023 was 33.03.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Alpine Immune Sciences could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Alpine Immune Sciences's Cash-to-Debt or its related term are showing as below:

STU:34LA' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.48 Med: 16.42 Max: No Debt
Current: 33.03

During the past 12 years, Alpine Immune Sciences's highest Cash to Debt Ratio was No Debt. The lowest was 2.48. And the median was 16.42.

STU:34LA's Cash-to-Debt is ranked better than
69.23% of 1537 companies
in the Biotechnology industry
Industry Median: 6.49 vs STU:34LA: 33.03

Alpine Immune Sciences Cash-to-Debt Historical Data

The historical data trend for Alpine Immune Sciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Alpine Immune Sciences Cash-to-Debt Chart

Alpine Immune Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

2.48

4.67

8.27

16.71

33.03

Alpine Immune Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															16.71	15.20	19.61	19.05	33.03

Competitive Comparison of Alpine Immune Sciences's Cash-to-Debt

For the Biotechnology subindustry, Alpine Immune Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alpine Immune Sciences's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alpine Immune Sciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Alpine Immune Sciences's Cash-to-Debt falls into.

Alpine Immune Sciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Alpine Immune Sciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	300.237	/	(0.836	+	8.255)
	=	33.03

Alpine Immune Sciences's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	300.237	/	(0.836	+	8.255)
	=	33.03

Alpine Immune Sciences (STU:34LA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Alpine Immune Sciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Alpine Immune Sciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Alpine Immune Sciences (STU:34LA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpine Immune Sciences Inc (STU:34LA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

ALPN:USA

Address

188 East Blaine Street, Suite 200, Seattle, WA, USA, 98102

Website

https://www.alpineimmunesciences.com

Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

Alpine Immune Sciences (STU:34LA) Headlines

No Headlines